| Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network AA Hakimi, I Ostrovnaya, B Reva, N Schultz, YB Chen, M Gonen, H Liu, ... Clinical Cancer Research 19 (12), 3259-3267, 2013 | 405 | 2013 |
| Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma AA Hakimi, YB Chen, J Wren, M Gonen, O Abdel-Wahab, A Heguy, H Liu, ... European Urology 63 (5), 848-54, 2013 | 264 | 2013 |
| Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy MH Voss, AA Hakimi, CG Pham, AR Brannon, YB Chen, LF Cunha, ... Clinical cancer research 20 (7), 1955-1964, 2014 | 224 | 2014 |
| Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint H Liu, S Takeda, R Kumar, TD Westergard, EJ Brown, TK Pandita, ... Nature 467 (7313), 343-346, 2010 | 175 | 2010 |
| PUMA and BIM Are Required for Oncogene Inactivation-Induced Apoptosis GR Bean, YT Ganesan, Y Dong, S Takeda, H Liu, PM Chan, Y Huang, ... Science Signaling 6 (268), ra20, 2013 | 150 | 2013 |
| MLL fusions H Liu, EHY Cheng, JJD Hsieh Cancer biology & therapy 8 (13), 1204-1211, 2009 | 142 | 2009 |
| Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions H Liu, EHY Cheng, JJD Hsieh Genes & development 21 (19), 2385, 2007 | 141 | 2007 |
| Respecifying human iPSC-derived blood cells into highly engraftable hematopoietic stem and progenitor cells with a single factor YT Tan, L Ye, F Xie, AI Beyer, MO Muench, J Wang, Z Chen, H Liu, ... Proceedings of the National Academy of Sciences 115 (9), 2180-2185, 2018 | 74 | 2018 |
| ΔNp63 inhibits oxidative stress-induced cell death, including ferroptosis, and cooperates with the BCL-2 family to promote clonogenic survival GX Wang, HC Tu, Y Dong, AJ Skanderup, Y Wang, S Takeda, ... Cell reports 21 (10), 2926-2939, 2017 | 73 | 2017 |
| Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation MM Ji, L Wang, Q Zhan, W Xue, Y Zhao, X Zhao, PP Xu, Y Shen, H Liu, ... Autophagy 11 (12), 2160-2171, 2015 | 73 | 2015 |
| HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma S Takeda, H Liu, S Sasagawa, Y Dong, PA Trainor, EH Cheng, JJ Hsieh The Journal of clinical investigation 123 (7), 3154-3165, 2013 | 66 | 2013 |
| Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4 H Liu, TD Westergard, A Cashen, DR Piwnica-Worms, L Kunkle, R Vij, ... Cancer Cell 25 (4), 530-542, 2014 | 56 | 2014 |
| Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis DY Chen, H Liu, S Takeda, HC Tu, S Sasagawa, BA Van Tine, D Lu, ... Cancer research 70 (13), 5358-5367, 2010 | 55 | 2010 |
| A Pharmacologic Inhibitor of the Protease Taspase1 Effectively Inhibits Breast and Brain Tumor Growth DY Chen, Y Lee, BA Van Tine, AC Searleman, TD Westergard, H Liu, ... Cancer Research 72 (3), 736-746, 2012 | 51 | 2012 |
| TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells D Li, Y Hu, Z Jin, Y Zhai, Y Tan, Y Sun, S Zhu, C Zhao, B Chen, J Zhu, ... Leukemia 32 (9), 2012-2016, 2018 | 47 | 2018 |
| Cancer cell derived small extracellular vesicles contribute to recipient cell metastasis through promoting HGF/c-Met pathway Z Qiao, Y Zhang, M Ge, S Liu, X Jiang, Z Shang, H Liu, C Cao, H Xiao Molecular & Cellular Proteomics 18 (8), 1619-1629, 2019 | 45 | 2019 |
| Biphasic MLL takes helm at cell cycle control H Liu, S Takeda, EHY Cheng, JJD Hsieh Cell Cycle 7 (4), 428-435, 2008 | 39 | 2008 |
| Functional contribution of EEN to leukemogenic transformation by MLL-EEN fusion protein H Liu, B Chen, H Xiong, QH Huang, QH Zhang, ZG Wang, BL Li, Z Chen, ... Oncogene 23 (19), 3385-3394, 2004 | 38 | 2004 |
| ccRCC Cancer Genome Atlas (KIRC TCGA) Research Network investigators. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and … AA Hakimi, I Ostrovnaya, B Reva, N Schultz, YB Chen, M Gonen, H Liu, ... Clin Cancer Res 19 (12), 3259-3267, 2013 | 35 | 2013 |
| MLL5 governs hematopoiesis: a step closer H Liu, TD Westergard, JJD Hsieh Blood, The Journal of the American Society of Hematology 113 (7), 1395-1396, 2009 | 22 | 2009 |